Lv33
340 积分 2022-08-30 加入
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
2天前
已完结
Time in tight range: A key metric for optimal glucose control in the era of advanced diabetes technologies and therapeutics
7天前
已关闭
A Glycemic Threshold Above Which the Improvement of β-Cell Function and Glycemia in Response to Insulin Therapy Is Amplified in Early Type 2 Diabetes: The Reversal of Glucotoxicity
7天前
已完结
Intensive Glycemic Management Is Associated With Reduced Retinal Structure Abnormalities on Ocular Coherence Tomography in the DCCT/EDIC Study
7天前
已关闭
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5)
16天前
已完结
Is glycaemic control still central in the hierarchy of priorities in type 2 diabetes management? The way forward is to combine glucose control and the prevention of cardiorenal complications
22天前
已完结
Glycaemic management in diabetes: old and new approaches
22天前
已完结
IcoSema’s leap forward: new data from COMBINE 3 paves the way
1个月前
已关闭
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial
1个月前
已完结
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
1个月前
已完结
皖公网安备34019202002308
